Is there a Role for ADORA2A Polymorphisms in Levodopa-Induced Dyskinesia in Parkinson’s Disease Patients?

References

• Lewis SJ , CaldwellMA , BarkerRA . Modern therapeutic approaches in Parkinson’s disease . Expert Rev. Mol. Med.5 ( 10 ), 1 – 20 ( 2003 ).
   PubMedGoogle Scholar
• Ahlskog JE , MuenterMD . Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature . Mov. Disord.16 ( 3 ), 448 – 458 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Jankovic J . Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations . Mov. Disord.20 ( Suppl. 11 ), S11 – S16 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Van Gerpen JA , KumarN , BowerJH , WeigandS , AhlskogJE . Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976–1990 . Arch. Neurol.63 ( 2 ), 205 – 209 ( 2006 ).
   PubMedGoogle Scholar
• Schumacher-Schuh AF , RiederCR , HutzMH . Parkinson’s disease pharmacogenomics: new findings and perspectives . Pharmacogenomics15 ( 9 ), 1253 – 1271 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Armentero MT , PinnaA , FerreS , LanciegoJL , MullerCE , FrancoR . Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson’s disease . Pharmacol. Ther.132 ( 3 ), 280 – 299 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Morelli M , Di PaoloT , WardasJ , CalonF , XiaoD , SchwarzschildMA . Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications . Prog. Neurobiol.83 ( 5 ), 293 – 309 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Schiffmann SN , FisoneG , MorescoR , CunhaRA , FerreS . Adenosine A2A receptors and basal ganglia physiology . Prog. Neurobiol.83 ( 5 ), 277 – 292 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Rieck M , Schumacher-SchuhAF , AltmannVet al. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson’s disease patients . Pharmacogenomics13 ( 15 ), 1701 – 1710 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Schumacher-Schuh AF , AltmannV , RieckMet al. Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson’s disease patients . Pharmacogenomics J.14 ( 3 ), 289 – 294 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hughes AJ , DanielSE , KilfordL , LeesAJ . Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases . J. Neurol. Neurosurg. Psychiatry55 ( 3 ), 181 – 184 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P , Gil-NagelA , GraciaLM , GomezJB , Martinez-SarriesJ , BermejoF . Unified Parkinson’s Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group . Mov. Disord.9 ( 1 ), 76 – 83 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Long J . Multiple Locus Haplotype Analysis, version 3.0: software and documentation distributed by the author . Department of Human Genetics, University of Michigan Medical School , Ann Arbor, MI, USA , 4819 – 0618 ( 1999 ).
   Google Scholar
• Stephens M , SmithNJ , DonnellyP . A new statistical method for haplotype reconstruction from population data . Am. J. Hum. Genet.68 ( 4 ), 978 – 989 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Stephens M , ScheetP . Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation . Am. J. Hum. Genet.76 ( 3 ), 449 – 462 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Greenland S . Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case–control studies . Am. J. Epidemiol.160 ( 4 ), 301 – 305 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Yu L , FrithMC , SuzukiYet al. Characterization of genomic organization of the adenosine A2A receptor gene by molecular and bioinformatics analyses . Brain Res.1000 ( 1–2 ), 156 – 173 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Conde L , VaquerizasJM , DopazoHet al. PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes . Nucleic Acids Res.34 ( Web Server issue ), W621 – W625 ( 2006 ).
   PubMedGoogle Scholar
• Guntaka RV , VarmaBR , WeberKT . Triplex-forming oligonucleotides as modulators of gene expression . Int. J. Biochem. Cell Biol.35 ( 1 ), 22 – 31 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Besch R , GiovannangeliC , DegitzK . Triplex-forming oligonucleotides – sequence-specific DNA ligands as tools for gene inhibition and for modulation of DNA-associated functions . Curr. Drug Targets5 ( 8 ), 691 – 703 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Goni JR , De La CruzX , OrozcoM . Triplex-forming oligonucleotide target sequences in the human genome . Nucleic Acids Res.32 ( 1 ), 354 – 360 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Ivanova SA , LoonenAJ , PechlivanoglouPet al. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia . Transl. Psychiatry2 , e67 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Loonen AJ , IvanovaSA . New insights into the mechanism of drug-induced dyskinesia . CNS Spectr.18 ( 1 ), 15 – 20 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kalia LV , BrotchieJM , FoxSH . Novel nondopaminergic targets for motor features of Parkinson’s disease: review of recent trials . Mov. Disord.28 ( 2 ), 131 – 144 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kanda T , JacksonMJ , SmithLAet al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys . Ann. Neurol.43 ( 4 ), 507 – 513 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Bibbiani F , OhJD , PetzerJPet al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease . Exp. Neurol.184 ( 1 ), 285 – 294 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Wei CJ , LiW , ChenJF . Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies . Biochim. Biophys. Acta1808 ( 5 ), 1358 – 1379 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Kulisevsky J , PoyurovskyM . Adenosine A2A-receptor antagonism and pathophysiology of Parkinson’s disease and drug-induced movement disorders . Eur. Neurol.67 ( 1 ), 4 – 11 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Hickey P , StacyM . Adenosine A2A antagonists in Parkinson’s disease: what’s next?Curr. Neurol. Neurosci. Rep.12 ( 4 ), 376 – 385 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Huot P , JohnstonTH , KoprichJB , FoxSH , BrotchieJM . The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease . Pharmacol. Rev.65 ( 1 ), 171 – 222 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Pollack AE , FinkJS . Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway . Neuroscience68 ( 3 ), 721 – 728 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Ochi M , KogaK , KurokawaM , KaseH , NakamuraJ , KuwanaY . Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study . Neuroscience100 ( 1 ), 53 – 62 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Ochi M , ShiozakiS , KaseH . Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson’s disease . Neuroscience127 ( 1 ), 223 – 231 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Fuxe K , FerreS , GenedaniS , FrancoR , AgnatiLF . Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function . Physiol. Behav.92 ( 1–2 ), 210 – 217 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Tozzi A , TscherterA , BelcastroVet al. Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission . Neuropharmacology53 ( 6 ), 783 – 789 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Tozzi A , De IureA , Di FilippoMet al. The distinct role of medium spiny neurons and cholinergic interneurons in the D(2)/A(2)A receptor interaction in the striatum: implications for Parkinson’s disease . J. Neurosci.31 ( 5 ), 1850 – 1862 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Varani K , VincenziF , TosiAet al. A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson’s disease . FASEB J.24 ( 2 ), 587 – 598 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Casetta I , VincenziF , BencivelliDet al. A(2A) adenosine receptors and Parkinson’s disease severity . Acta Neurol. Scand.129 ( 4 ), 276 – 281 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Villar-Menendez I , PortaS , BuiraSPet al. Increased striatal adenosine A2A receptor levels is an early event in Parkinson’s disease-related pathology and it is potentially regulated by miR-34b . Neurobiol. Dis.69 , 206 – 214 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Calon F , DridiM , HornykiewiczO , BedardPJ , RajputAH , Di PaoloT . Increased adenosine A2A receptors in the brain of Parkinson’s disease patients with dyskinesias . Brain127 ( Pt 5 ), 1075 – 1084 ( 2004 ).
   PubMedGoogle Scholar
• Mishina M , IshiwataK , NaganawaMet al. Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson’s disease patients . PLoS ONE6 ( 2 ), e17338 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ramlackhansingh AF , BoseSK , AhmedI , TurkheimerFE , PaveseN , BrooksDJ . Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease . Neurology76 ( 21 ), 1811 – 1816 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Chen JF , SonsallaPK , PedataFet al. Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and ‘fine tuning’ modulation . Prog. Neurobiol.83 ( 5 ), 310 – 331 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Chen JF , EltzschigHK , FredholmBB . Adenosine receptors as drug targets – what are the challenges?Nat. Rev. Drug Discov.12 ( 4 ), 265 – 286 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Khoa ND , MontesinosMC , ReissAB , DelanoD , AwadallahN , CronsteinBN . Inflammatory cytokines regulate function and expression of adenosine A(2A) receptors in human monocytic THP-1 cells . J. Immunol.167 ( 7 ), 4026 – 4032 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Kermanian F , SoleimaniM , EbrahimzadehA , HaghirH , MehdizadehM . Effects of adenosine A2a receptor agonist and antagonist on hippocampal nuclear factor-kB expression preceded by MDMA toxicity . Metab. Brain Dis.28 ( 1 ), 45 – 52 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Bontempi S , FiorentiniC , BusiC , GuerraN , SpanoP , MissaleC . Identification and characterization of two nuclear factor-kappaB sites in the regulatory region of the dopamine D2 receptor . Endocrinology148 ( 5 ), 2563 – 2570 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Childs E , HohoffC , DeckertJ , XuK , BadnerJ , De WitH . Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety . Neuropsychopharmacology33 ( 12 ), 2791 – 2800 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Freitag CM , AgelopoulosK , HuyEet al. Adenosine A(2A) receptor gene (ADORA2A) variants may increase autistic symptoms and anxiety in autism spectrum disorder . Eur Child Adolesc Psychiatry19 ( 1 ), 67 – 74 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Hohoff C , MullingsEL , HeatherleySVet al. Adenosine A(2A) receptor gene: evidence for association of risk variants with panic disorder and anxious personality . J. Psychiatr Res.44 ( 14 ), 930 – 937 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Jagannathan K , CalhounVD , GelernterJet al. Genetic associations of brain structural networks in schizophrenia: a preliminary study . Biol. Psychiatry68 ( 7 ), 657 – 666 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Rogers PJ , HohoffC , HeatherleySVet al. Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption . Neuropsychopharmacology35 ( 9 ), 1973 – 1983 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Beste C , StockAK , NessV , EpplenJT , ArningL . Differential effects of ADORA2A gene variations in preattentive visual sensory memory subprocesses . Eur. Neuropsychopharmacol.22 ( 8 ), 555 – 561 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Popat RA , Van Den EedenSK , TannerCMet al. Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease . Eur. J. Neurol.18 ( 5 ), 756 – 765 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Greenbaum L , CohenOS , InzelbergRet al. Association of the adenosine receptor A2A (ADORA2A) gene with L-dopa induced dyskinesia in Parkinson’s disease [abstract] . Mov. Disord.27 ( Suppl. 1 ), 1385 ( 2012 ).
   Google Scholar
• Perneger TV . What’s wrong with Bonferroni adjustments . BMJ316 ( 7139 ), 1236 – 1238 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Colosimo C , Martinez-MartinP , FabbriniGet al. Task force report on scales to assess dyskinesia in Parkinson’s disease: critique and recommendations . Mov. Disord.25 ( 9 ), 1131 – 1142 ( 2010 ).
   PubMed Web of Science ®Google Scholar